- Home
- KRG vs TMDX Comparison
KRG vs TMDX Comparison
Compare KRG & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRG
- TMDX
- Stock Information
- Founded
- KRG 1971
- TMDX 1998
- Country
- KRG United States
- TMDX United States
- Employees
- KRG N/A
- TMDX N/A
- Industry
- KRG Real Estate Investment Trusts
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KRG Real Estate
- TMDX Health Care
- Exchange
- KRG Nasdaq
- TMDX Nasdaq
- Market Cap
- KRG 5.0B
- TMDX 4.8B
- IPO Year
- KRG 2004
- TMDX 2019
- Fundamental
- Price
- KRG $22.53
- TMDX $113.93
- Analyst Decision
- KRG Buy
- TMDX Buy
- Analyst Count
- KRG 8
- TMDX 10
- Target Price
- KRG $27.25
- TMDX $127.33
- AVG Volume (30 Days)
- KRG 1.5M
- TMDX 843.5K
- Earning Date
- KRG 07-30-2025
- TMDX 07-30-2025
- Dividend Yield
- KRG 4.80%
- TMDX N/A
- EPS Growth
- KRG N/A
- TMDX N/A
- EPS
- KRG 0.06
- TMDX 1.41
- Revenue
- KRG $856,165,000.00
- TMDX $488,227,000.00
- Revenue This Year
- KRG $3.11
- TMDX $34.07
- Revenue Next Year
- KRG $3.08
- TMDX $20.76
- P/E Ratio
- KRG $370.62
- TMDX $79.83
- Revenue Growth
- KRG 3.94
- TMDX 64.43
- 52 Week Low
- KRG $18.52
- TMDX $55.00
- 52 Week High
- KRG $28.24
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- KRG 50.09
- TMDX 34.85
- Support Level
- KRG $22.20
- TMDX $122.48
- Resistance Level
- KRG $22.69
- TMDX $127.97
- Average True Range (ATR)
- KRG 0.42
- TMDX 5.69
- MACD
- KRG -0.05
- TMDX -2.22
- Stochastic Oscillator
- KRG 35.61
- TMDX 17.42
About KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.